MCID: CLR108
MIFTS: 63

Colorectal Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenoma

MalaCards integrated aliases for Colorectal Adenoma:

Name: Colorectal Adenoma 12 29 6 15 17
Adenoma of Large Intestine 70
Colorectal Adenomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050860
UMLS 70 C1302401

Summaries for Colorectal Adenoma

Disease Ontology : 12 An intestinal benign neoplasm that has material basis in epithelial tissue of glandular origin and is located in colon and located in rectum.

MalaCards based summary : Colorectal Adenoma, also known as adenoma of large intestine, is related to mismatch repair cancer syndrome 1 and adenoma. An important gene associated with Colorectal Adenoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and TCR Signaling (Qiagen). The drugs Celecoxib and Rofecoxib have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and prostate, and related phenotypes are Increased shRNA abundance and homeostasis/metabolism

Wikipedia : 73 The colorectal adenoma is a benign glandular tumor of the colon and the rectum. It is a precursor lesion... more...

Related Diseases for Colorectal Adenoma

Diseases related to Colorectal Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 481)
# Related Disease Score Top Affiliating Genes
1 mismatch repair cancer syndrome 1 31.7 MSH2 MLH1 CTNNB1 APC
2 adenoma 31.4 TP53 PTGS2 ODC1 MUTYH MSH2 MLH1
3 colon adenoma 31.0 MIR15A KRAS CTNNB1 APC
4 familial adenomatous polyposis 2 30.8 PTGS2 MUTYH MLH1 APC
5 villous adenoma 30.7 TP53 MLH1 KRAS HRAS APC
6 proteasome-associated autoinflammatory syndrome 1 30.6 PTGS2 INS IL6
7 serrated polyposis syndrome 30.5 MUTYH KRAS APC
8 attenuated familial adenomatous polyposis 30.5 MUTYH MSH2 APC
9 gastritis 30.4 TP53 PTGS2 ODC1 IL6
10 peutz-jeghers syndrome 30.3 TP53 CTNNB1 APC
11 mucinous adenocarcinoma 30.3 TP53 MLH1 KRAS
12 hereditary nonpolyposis colon cancer 30.3 MUTYH MSH2 MLH1
13 liver cirrhosis 30.3 TP53 INS IL6 CTNNB1 APC
14 atrophic gastritis 30.2 TP53 PTGS2 ODC1 IL6 ERCC6
15 hepatoblastoma 30.2 TP53 MYC IL6 CTNNB1 APC
16 barrett esophagus 30.1 TP53 PTGS2 ODC1 MYC CTNNB1 APC
17 familial colorectal cancer 30.1 TP53 MUTYH MSH2 MLH1 APC
18 mismatch repair cancer syndrome 30.0 MSH2 MLH1
19 adenocarcinoma 30.0 TP53 PTGS2 MYC MSH2 MLH1 KRAS
20 in situ carcinoma 30.0 TP53 MYC MIR17 HRAS CTNNB1
21 peptic ulcer disease 29.9 TP53 PTGS2 HRAS
22 non-alcoholic fatty liver disease 29.9 TP53 MIR21 MIR17 INS IL6
23 colitis 29.9 PTGS2 MSH2 MLH1 IL6 CTNNB1
24 appendix adenocarcinoma 29.9 KRAS HRAS
25 gastric adenocarcinoma 29.8 TP53 PTGS2 MLH1 KRAS HRAS CTNNB1
26 hepatitis b 29.8 TP53 MYC MIR21 MIR17 IL6
27 deficiency anemia 29.8 MTR INS IL6 ERCC6 APC
28 myh-associated polyposis 29.8 MUTYH MSH2 KRAS HRAS APC
29 juvenile polyposis syndrome 29.8 PTGS2 MUTYH MSH2 MLH1 APC
30 overnutrition 29.8 MIR21 MIR17 INS IL6
31 osteoporosis 29.7 TP53 PTGS2 MTHFR MIR21 INS IL6
32 inflammatory bowel disease 29.7 TP53 PTGS2 MYC MTHFR MLH1 MIR21
33 colorectal adenocarcinoma 29.6 TP53 PTGS2 MYC MSH2 MLH1 KRAS
34 ulcerative colitis 29.6 MSH2 MLH1 IL6 CTNNB1
35 basal cell carcinoma 29.6 TP53 PTGS2 MSH2 MLH1 IL6 CTNNB1
36 familial adenomatous polyposis 29.5 TP53 PTGS2 ODC1 MYC MUTYH MSH2
37 lipoprotein quantitative trait locus 29.5 MTR MTHFR MIR21 MIR17 INS IL6
38 ascending colon cancer 29.4 MSH2 MLH1 KRAS HRAS
39 arteries, anomalies of 29.3 MIR21 MIR17 MIR15A INS IL6
40 gallbladder disease 29.3 TP53 MIR17 KRAS INS HRAS CTNNB1
41 colon adenocarcinoma 29.3 TP53 PTGS2 ODC1 MYC MLH1 MIR21
42 intracranial meningioma 29.3 MSH2 MLH1
43 duodenum cancer 29.2 TP53 MUTYH MSH2 MLH1 KRAS HRAS
44 medulloblastoma 29.1 TP53 PTGS2 ODC1 MYC MIR17 IL6
45 rectum cancer 29.0 MUTYH MSH2 MLH1 MIR21 MIR17 KRAS
46 endometrial cancer 29.0 TP53 MYC MUTYH MSH2 MLH1 KRAS
47 esophageal cancer 28.8 TP53 PTGS2 MYC MTHFR MLH1 MIR21
48 lynch syndrome 28.8 TP53 MUTYH MTHFR MSH2 MLH1 MIR17
49 li-fraumeni syndrome 28.8 TP53 MYC MUTYH MSH2 MLH1 KRAS
50 cervical cancer 28.6 TP53 PTGS2 MYC MIR21 MIR17 MIR15A

Graphical network of the top 20 diseases related to Colorectal Adenoma:



Diseases related to Colorectal Adenoma

Symptoms & Phenotypes for Colorectal Adenoma

GenomeRNAi Phenotypes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.1 APC INS MLH1 MTHFR MTR MUTYH

MGI Mouse Phenotypes related to Colorectal Adenoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 APC CTNNB1 ERCC6 HPGD HRAS IL6
2 cellular MP:0005384 10.4 APC CTNNB1 ERCC6 HPGD IL6 INS
3 mortality/aging MP:0010768 10.39 APC CTNNB1 ERCC6 HPGD HRAS IL6
4 integument MP:0010771 10.32 APC CTNNB1 ERCC6 HRAS IL6 INS
5 digestive/alimentary MP:0005381 10.29 APC CTNNB1 HRAS IL6 INS KRAS
6 endocrine/exocrine gland MP:0005379 10.28 APC CTNNB1 HPGD HRAS IL6 INS
7 liver/biliary system MP:0005370 10.18 APC CTNNB1 ERCC6 IL6 INS KRAS
8 neoplasm MP:0002006 10.18 APC CTNNB1 ERCC6 HRAS IL6 KRAS
9 nervous system MP:0003631 10.18 APC CTNNB1 ERCC6 HRAS IL6 INS
10 muscle MP:0005369 10.13 APC CTNNB1 ERCC6 HRAS IL6 INS
11 limbs/digits/tail MP:0005371 10.04 APC CTNNB1 ERCC6 KRAS MTHFR MYC
12 no phenotypic analysis MP:0003012 9.92 CTNNB1 HRAS INS KRAS MTHFR MYC
13 normal MP:0002873 9.91 APC CTNNB1 HRAS INS KRAS MYC
14 renal/urinary system MP:0005367 9.76 APC CTNNB1 HRAS IL6 INS KRAS
15 reproductive system MP:0005389 9.7 APC CTNNB1 HPGD IL6 INS KRAS
16 skeleton MP:0005390 9.36 APC CTNNB1 ERCC6 HRAS IL6 INS

Drugs & Therapeutics for Colorectal Adenoma

Drugs for Colorectal Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
2
Rofecoxib Approved, Investigational, Withdrawn Phase 3 162011-90-7 5090
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Zinc Approved, Investigational Phase 3 7440-66-6 32051
5
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
6
Tocopherol Approved, Investigational Phase 3 1406-66-2
7
Calcium carbonate Approved, Investigational Phase 3 471-34-1
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
9
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 5280795 6221
10
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
13
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 5280453 134070
14 Tocotrienol Investigational Phase 3 6829-55-6
15 Calciferol Phase 2, Phase 3
16 Cyclooxygenase 2 Inhibitors Phase 3
17 Acetylsalicylic acid lysinate Phase 3
18 Cola Phase 3
19 Vitamins Phase 3
20 Calcium, Dietary Phase 3
21 Analgesics, Non-Narcotic Phase 3
22 Cyclooxygenase Inhibitors Phase 3
23 Analgesics Phase 3
24 Fibrinolytic Agents Phase 3
25 Antirheumatic Agents Phase 3
26 Anti-Inflammatory Agents Phase 3
27 Antipyretics Phase 3
28 Anti-Inflammatory Agents, Non-Steroidal Phase 3
29 Platelet Aggregation Inhibitors Phase 3
30 Nutrients Phase 3
31 Trace Elements Phase 3
32 Micronutrients Phase 3
33 retinol Phase 3
34 Retinol palmitate Phase 3
35 Protective Agents Phase 3
36 Antioxidants Phase 3
37 Tocotrienols Phase 3
38 Tocopherols Phase 3
39 Gastrointestinal Agents Phase 3
40 Dihydroxycholecalciferols Phase 3
41 Vasoconstrictor Agents Phase 3
42 Antacids Phase 3
43 Hormones Phase 3
44 Anti-Ulcer Agents Phase 3
45
Calcium Nutraceutical Phase 3 7440-70-2 271
46
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
47
Metformin Approved Phase 2 657-24-9 4091 14219
48
Linaclotide Approved Phase 2 851199-59-2 65351
49
Catechin Approved, Withdrawn Phase 2 154-23-4 9064
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
2 A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer Unknown status NCT03281096 Phase 2, Phase 3 Berberine hydrochloride;Placebo
3 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
4 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
5 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
6 Prevention of Sporadic Colorectal Adenomas With Celecoxib Completed NCT00005094 Phase 3 celecoxib
7 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
8 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
9 The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial Recruiting NCT03333265 Phase 2, Phase 3 100mg Berberine hydrochloride;300mg Berberine hydrochloride;Placebo Oral Tablet
10 Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Recruiting NCT02813824 Phase 3 Acetylsalicylic acid lysinate 300 mg;Placebo (for Aspirin 300);Acetylsalicylic acid lysinate 100 mg;Placebo 100 (for Aspirin 100)
11 Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial Terminated NCT01437826 Phase 3 antioxidants;placebo
12 A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas Terminated NCT00486512 Phase 3 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol);75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3);placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol);placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
13 Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence Terminated NCT00224679 Phase 3 Aspirin
14 Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE- Completed NCT01360320 Phase 2
15 Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas Completed NCT01894685 Phase 2 Mesalazine;Placebo
16 Randomized, Placebo-Controlled, Phase 2B Evaluation of Cyclooxygenase-2 Activity in Surgically Resected Primary Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
17 A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index Completed NCT01312467 Phase 2 metformin hydrochloride
18 3389 Colorectal Adenoma: Chemoprevention With Folic Acid Completed NCT00018551 Phase 2 Folic Acid
19 Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma Completed NCT00773097 Phase 2
20 Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer Recruiting NCT03796884 Phase 2 Linaclotide
21 Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention Recruiting NCT02965703 Phase 2 Aspirin
22 PREPARE: PRevention Using EPA Against coloREctal Cancer Active, not recruiting NCT04216251 Phase 1, Phase 2 AMR101
23 Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas Active, not recruiting NCT02134925 Phase 2
24 Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia Terminated NCT01606124 Phase 2 defined green tea catechin extract
25 Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Withdrawn NCT03185871 Phase 2 Celecoxib
26 Multicenter, Randomised Controlled Trial Comparing Endoscopic Mucosal Resection (EMR) And Endoscopic Submucosal dissecTIon (ESD) for Resection of Large Distal Non-pedunculated Colorectal Adenomas (MATILDA-trial) Unknown status NCT02657044
27 Development of a New Generation Multi Parametric Test for Prediction of Colorectal Neoplasia Recurrence Unknown status NCT03434925
28 Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"- A Prospective Multicenter Trial Unknown status NCT02362126
29 Detection of Colorectal Adenomas in Côte-d'Or: Impact of Organized Screening on Socio-geographic Disparities Unknown status NCT02859714
30 UKCAP Trial: A Multi-Center Double Blind Randomised Controlled Trial Of Aspirin And/Or Folate Supplementation For the Prevention Of Recurrent Colorectal Adenomas Unknown status NCT00033319 acetylsalicylic acid
31 Clinical Study That Effect of Individualized Intervention of Single Colonoscopy on Colorectal Adenomas Detection Unknown status NCT02693886
32 Comparison of Detection and Miss Rates of Colorectal Adenoma by Blue Laser Imaging (BLI) Versus Conventional White Light Colonoscopy. Unknown status NCT02982447
33 Investigation of the Role of the Microbiome in the Pathogenesis of Colorectal Adenoma and Carcinoma Unknown status NCT02947607
34 Randomized Window of Opportunity Trial of Anthocyanin Extract and Phospholipid Curcumin in Subjects With Colorectal Adenoma Unknown status NCT01948661
35 Colorectal Adenoma Screening by Low-dose CT Colonoscopy With Computer-aided Detection Unknown status NCT03064828
36 Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy: A Randomized Trial Unknown status NCT02865382
37 Prevalence of Colorectal Adenoma in 30- to 49-year-old Asymptomatic Subjects With a First Relative History of Colorectal Cancer Unknown status NCT01428752
38 A Pilot Study to Assess the Role for Endocuff© Assisted Colonoscopy in the Detection of Colonic Cancer and Polyps Unknown status NCT01761097
39 Efficacy of Segmental Re-examination and Retroflexion of Proximal Colon for Adenoma Miss Rate During Colonoscopy Unknown status NCT03355443
40 Novel Blood-based Colorectal Cancer Screening Method Using Natural Killer Cell Activity and Gene Panel Expression Unknown status NCT03289988
41 Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique Unknown status NCT02935049
42 Intubation Techniques on Colonoscopy Quality: A Single Center Randomized Control Clinical Trial Unknown status NCT01919463
43 ObeSity Related Colorectal Adenoma Risk Completed NCT03663062
44 Chromoendoscopy in Lynch Syndrome Patients Completed NCT00905710
45 Predictive Factors for Failure or Success of Endoscopic Treatment of Superficial Colorectal Tumors Completed NCT03470883
46 Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention Completed NCT00399607
47 GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps Completed NCT02595645
48 The Biomarkers Of RIsk of Colorectal Cancer (BORICC) Follow-Up (BFU) Study Completed NCT04005742
49 Comparison of Adenoma Detection by Polypectomy During Both Insertion and Withdrawal Versus Only Withdrawal of Colonoscopy: a Randomized, Controlled Trial Completed NCT01925833
50 The Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS) Folic Acid Prevention Trial Completed NCT00512850

Search NIH Clinical Center for Colorectal Adenoma

Genetic Tests for Colorectal Adenoma

Genetic tests related to Colorectal Adenoma:

# Genetic test Affiliating Genes
1 Colorectal Adenoma 29

Anatomical Context for Colorectal Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Adenoma:

19
Colon, Rectum

MalaCards organs/tissues related to Colorectal Adenoma:

40
Colon, Prostate, Breast, Endothelial, Liver, Lymph Node, Thyroid

Publications for Colorectal Adenoma

Articles related to Colorectal Adenoma:

(show top 50) (show all 3945)
# Title Authors PMID Year
1
Aberrant expression of m6A mRNA methylation regulators in colorectal adenoma and adenocarcinoma. 61
33636176 2021
2
Accurate measurement of colorectal polyps using computer-aided analysis. 61
33787542 2021
3
Circulating 27-hydroxycholesterol and Risk of Colorectal Adenomas and Serrated Polyps. 61
33408073 2021
4
Early stage clear cell adenocarcinoma coexisting with tubular adenoma and adenoma with clear cell change in the colon. 61
33420668 2021
5
Aspects of colorectal cancer screening, methods, age and gender. 61
32929813 2021
6
Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. 61
32428708 2021
7
Reduction in the resident intestinal myelomonocytic cell population occurs during ApcMin/+ mouse intestinal tumorigenesis. 61
33664826 2021
8
Differential Expression Profiles of Mitogenome Associated MicroRNAs Among Colorectal Adenomatous Polyps. 61
33628862 2021
9
Oxylipin patterns in human colon adenomas. 61
33812217 2021
10
Immunohistochemical expression of β-catenin, Ki67, CD3 and CD18 in canine colorectal adenomas and adenocarcinomas. 61
33712002 2021
11
5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. 61
33785874 2021
12
Prevalence of Mismatch Repair-Deficient Colorectal Adenoma/Polyp in Early-Onset, Advanced Cases: a Cross-Sectional Study Based on Iranian Hereditary Colorectal Cancer Registry. 61
32193764 2021
13
Impact of menopausal hormone therapy on colorectal cancer risk-A systematic review. 61
33752259 2021
14
National Colorectal Cancer Screening Program in Lithuania: Description of the 5-Year Performance on Population Level. 61
33800772 2021
15
Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. 61
33682036 2021
16
ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer. 61
33648461 2021
17
Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis. 61
33743605 2021
18
Serum angiogenin as a potential biomarker for early detection of colorectal adenomas and colorectal cancer. 61
33661188 2021
19
Comprehensive Analysis of microRNA Profiles in Organoids Derived from Human Colorectal Adenoma and Cancer. 61
33647915 2021
20
Dairy intake during adolescence and risk of colorectal adenoma later in life. 61
33398066 2021
21
Association of body fat distribution and metabolic syndrome with the occurrence of colorectal adenoma: A case-control study. 61
33656773 2021
22
Prediction of the histology of colorectal neoplasm in white light colonoscopic images using deep learning algorithms. 61
33674628 2021
23
Tailoring Surveillance Colonoscopy in Patients with Advanced Adenomas. 61
33775897 2021
24
Double-clip traction could be superior to the pocket-creation method with cylindrical cap for colonic ESD: a randomized study in an ex vivo model. 61
33398562 2021
25
Evaluation of blue laser endoscopy for detecting colorectal non-pedunculated adenoma. 61
33736947 2021
26
Immunohistochemical Assessment of Transthyretin Association with Colorectal Adenocarcinoma. 61
33739034 2021
27
Incidental morphological findings in colorectal adenomas. 61
32981102 2021
28
Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study. 61
33249197 2021
29
Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. 61
33594505 2021
30
Variation rs9929218 and risk of the colorectal Cancer and adenomas: A meta-analysis. 61
33627078 2021
31
Nutritional prevention of colorectal cancer. 61
32019626 2021
32
Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas. 61
33669644 2021
33
miR-4477b gene as a novel pathogenic mutation occurring during the transformation of colorectal adenoma into colorectal cancer. 61
33708425 2021
34
Exogenous and endogenous sources of serine contribute to colon cancer metabolism, growth, and resistance to 5-fluorouracil. 61
33526512 2021
35
Re-engineering of peptides with high binding affinity to develop an advanced electrochemical sensor for colon cancer diagnosis. 61
33461708 2021
36
Nut and legume consumption and human health: an umbrella review of observational studies. 61
33541169 2021
37
Identification of a Novel Pathogenic Rearrangement Variant of the APC Gene Associated with a Variable Spectrum of Familial Cancer. 61
33670908 2021
38
Non-exposed device-assisted endoscopic full-thickness resection (FTRD) for a challenging colorectal adenoma recurrence after endoscopic mucosal resection using a test cap. 61
32648142 2021
39
The association between Fusobacterium nucleatum and cancer colorectal: a systematic review and meta-analysis. 61
33632539 2021
40
Presence of Metabolic Syndrome and Thyroid Nodules in Subjects with Colorectal Polyps. 61
33518699 2021
41
Comparison of Risk of Metachronous Advanced Colorectal Neoplasia in Patients with Sporadic Adenomas Aged < 50 Versus ≥ 50 years: A Systematic Review and Meta-Analysis. 61
33673304 2021
42
Perianal Paget's disease as spread from non-invasive colorectal adenomas. 61
32705713 2021
43
Divergent detection rates of fecal immunochemical test and questionnaire-based risk assessment for detecting proximal and distal advanced colorectal adenomas. 61
33410637 2021
44
Association of Colonic Diverticula with Colorectal Adenomas and Cancer. 61
33504050 2021
45
Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study). 61
33413599 2021
46
Tissue mRNA for S100A4, S100A6, S100A8, S100A9, S100A11 and S100P Proteins in Colorectal Neoplasia: A Pilot Study. 61
33466593 2021
47
Network Pharmacology and Molecular Docking on the Molecular Mechanism of Luo-hua-zi-zhu (LHZZ) Granule in the Prevention and Treatment of Bowel Precancerous Lesions. 61
33692692 2021
48
White Opaque Substance, a New Optical Marker on Magnifying Endoscopy: Usefulness in Diagnosing Colorectal Epithelial Neoplasms. 61
33434962 2021
49
No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. 61
32062040 2021
50
Wnt7a Promotes the Occurrence and Development of Colorectal Adenocarcinoma. 61
33791195 2021

Variations for Colorectal Adenoma

ClinVar genetic disease variations for Colorectal Adenoma:

6 (show all 13)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APC NM_000038.6(APC):c.2847G>T (p.Met949Ile) SNV Uncertain significance 161206 rs147394539 GRCh37: 5:112174138-112174138
GRCh38: 5:112838441-112838441
2 APC NM_000038.6(APC):c.4336G>A (p.Ala1446Thr) SNV Uncertain significance 127294 rs146572883 GRCh37: 5:112175627-112175627
GRCh38: 5:112839930-112839930
3 APC NM_000038.6(APC):c.4360A>G (p.Lys1454Glu) SNV Uncertain significance 127295 rs111866410 GRCh37: 5:112175651-112175651
GRCh38: 5:112839954-112839954
4 APC NM_000038.6(APC):c.4420G>A (p.Ala1474Thr) SNV Uncertain significance 133530 rs139387758 GRCh37: 5:112175711-112175711
GRCh38: 5:112840014-112840014
5 APC NM_000038.6(APC):c.4732T>G (p.Cys1578Gly) SNV Uncertain significance 140839 rs138367627 GRCh37: 5:112176023-112176023
GRCh38: 5:112840326-112840326
6 APC NM_000038.6(APC):c.7717A>G (p.Ile2573Val) SNV Uncertain significance 41536 rs145444830 GRCh37: 5:112179008-112179008
GRCh38: 5:112843311-112843311
7 APC NM_000038.6(APC):c.8266A>G (p.Ile2756Val) SNV Uncertain significance 135724 rs146115809 GRCh37: 5:112179557-112179557
GRCh38: 5:112843860-112843860
8 APC NM_000038.6(APC):c.3479C>A (p.Thr1160Lys) SNV Uncertain significance 41503 rs201004111 GRCh37: 5:112174770-112174770
GRCh38: 5:112839073-112839073
9 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg) SNV Uncertain significance 141928 rs371085910 GRCh37: 5:112111352-112111352
GRCh38: 5:112775655-112775655
10 APC NM_000038.6(APC):c.4237A>G (p.Met1413Val) SNV Likely benign 133510 rs141519952 GRCh37: 5:112175528-112175528
GRCh38: 5:112839831-112839831
11 APC NM_000038.6(APC):c.6985A>G (p.Ile2329Val) SNV Likely benign 135716 rs146048493 GRCh37: 5:112178276-112178276
GRCh38: 5:112842579-112842579
12 APC NM_000038.6(APC):c.7778A>G (p.Asn2593Ser) SNV Likely benign 161205 rs367676584 GRCh37: 5:112179069-112179069
GRCh38: 5:112843372-112843372
13 APC NM_000038.6(APC):c.8383G>A (p.Ala2795Thr) SNV Likely benign 141047 rs369264968 GRCh37: 5:112179674-112179674
GRCh38: 5:112843977-112843977

Expression for Colorectal Adenoma

LifeMap Discovery
Genes differentially expressed in tissues of Colorectal Adenoma patients vs. healthy controls: 35 (show top 50) (show all 254)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GCG glucagon Colon - 9.14 0.000
2 GUCA2B guanylate cyclase activator 2B Colon - 8.78 0.000
3 MS4A12 membrane spanning 4-domains A12 Colon - 8.78 0.000
4 AQP8 aquaporin 8 Colon - 8.30 0.000
5 CA1 carbonic anhydrase 1 Colon - 8.11 0.000
6 CLCA4 chloride channel accessory 4 Colon - 7.63 0.000
7 CA4 carbonic anhydrase 4 Colon - 7.51 0.000
8 TCN1 transcobalamin 1 Colon + 7.34 0.000
9 CLDN8 claudin 8 Colon - 7.18 0.000
10 CDH3 cadherin 3 Colon + 6.97 0.000
11 GUCA2A guanylate cyclase activator 2A Colon - 6.92 0.000
12 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Colon - 6.85 0.001
13 PRAC1 PRAC1 small nuclear protein Colon - 6.72 0.040
14 CEMIP cell migration inducing hyaluronidase 1 Colon + 6.69 0.000
15 INSL5 insulin like 5 Colon - 6.67 0.000
16 PYY peptide YY Colon - 6.57 0.000
17 SCNN1B sodium channel epithelial 1 subunit beta Colon - 6.53 0.000
18 CHGA chromogranin A Colon - 6.30 0.000
19 SST somatostatin Colon - 5.99 0.000
20 ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) Colon - 5.77 0.002
21 SLC51B solute carrier family 51 subunit beta Colon - 5.54 0.001
22 CD177 CD177 molecule Colon - 5.52 0.003
23 GCNT2 glucosaminyl (N-acetyl) transferase 2 (I blood group) Colon - 5.48 0.000
24 SLC25A34 solute carrier family 25 member 34 Colon - 5.43 0.000
25 SLC26A3 solute carrier family 26 member 3 Colon - 5.39 0.002
26 CDKN2B cyclin dependent kinase inhibitor 2B Colon - 5.35 0.000
27 ZG16 zymogen granule protein 16 Colon - 5.34 0.000
28 MSX2 msh homeobox 2 Colon + 5.31 0.000
29 FABP6 fatty acid binding protein 6 Colon + 5.29 0.000
30 EPHX4 epoxide hydrolase 4 Colon + 5.24 0.000
31 STYXL2 serine/threonine/tyrosine interacting like 2 Colon + 5.23 0.000
32 TACSTD2 tumor associated calcium signal transducer 2 Colon + 5.10 0.000
33 GABRP gamma-aminobutyric acid type A receptor subunit pi Colon + 5.08 0.003
34 BEST4 bestrophin 4 Colon - 5.08 0.001
35 S100A2 S100 calcium binding protein A2 Colon + 5.05 0.000
36 DPEP1 dipeptidase 1 Colon + 5.04 0.010
37 MUC12 mucin 12, cell surface associated Colon - 4.98 0.020
38 SPINK5 serine peptidase inhibitor Kazal type 5 Colon - 4.96 0.001
39 PCSK1 proprotein convertase subtilisin/kexin type 1 Colon + 4.92 0.008
40 SLC30A10 solute carrier family 30 member 10 Colon - 4.89 0.003
41 TMEM72 transmembrane protein 72 Colon - 4.88 0.000
42 KLK10 kallikrein related peptidase 10 Colon + 4.85 0.020
43 CDH19 cadherin 19 Colon - 4.83 0.001
44 CDKN2B-AS1 CDKN2B antisense RNA 1 Colon - 4.75 0.004
45 MT1M metallothionein 1M Colon - 4.75 0.027
46 SLC6A19 solute carrier family 6 member 19 Colon - 4.71 0.007
47 PCK1 phosphoenolpyruvate carboxykinase 1 Colon - 4.70 0.000
48 ANO5 anoctamin 5 Colon - 4.68 0.000
49 FOXQ1 forkhead box Q1 Colon + 4.62 0.000
50 CEACAM7 CEA cell adhesion molecule 7 Colon - 4.60 0.001
Search GEO for disease gene expression data for Colorectal Adenoma.

Pathways for Colorectal Adenoma

Pathways related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 TP53 PTGS2 KRAS INS IL6 HRAS
2
Show member pathways
12.94 TP53 PTGS2 MSH2 MLH1 KRAS HRAS
3
Show member pathways
12.93 TP53 PTGS2 MYC KRAS IL6 HRAS
4
Show member pathways
12.89 TP53 PTGS2 MYC KRAS INS IL6
5
Show member pathways
12.8 MYC KRAS INS IL6 HRAS
6 12.78 TP53 MYC KRAS INS HRAS
7
Show member pathways
12.75 TP53 MYC MLH1 KRAS HRAS CTNNB1
8
Show member pathways
12.72 TP53 PTGS2 KRAS HRAS CTNNB1 APC
9
Show member pathways
12.66 TP53 MYC MSH2 MLH1 KRAS INS
10
Show member pathways
12.65 TP53 MYC KRAS IL6 HRAS
11 12.58 TP53 PTGS2 MYC MSH2 MLH1 KRAS
12
Show member pathways
12.53 TP53 MYC MSH2 KRAS IL6 HRAS
13
Show member pathways
12.52 TP53 KRAS INS HRAS APC
14
Show member pathways
12.52 TP53 MYC KRAS HRAS CTNNB1
15 12.43 TP53 PTGS2 MYC CTNNB1 APC
16
Show member pathways
12.42 PTGS2 KRAS HRAS CTNNB1
17
Show member pathways
12.42 KRAS IL6 HRAS CTNNB1 APC
18
Show member pathways
12.37 MYC KRAS HRAS CTNNB1
19 12.35 TP53 MYC KRAS IL6 HRAS
20
Show member pathways
12.32 TP53 IL6 HRAS CTNNB1 APC
21
Show member pathways
12.32 TP53 PTGS2 MTR MTHFR INS IL6
22 12.3 TP53 MYC IL6 HPGD
23 12.27 TP53 MYC MIR21 KRAS HRAS CTNNB1
24
Show member pathways
12.26 TP53 MYC CTNNB1 APC
25
Show member pathways
12.24 PTGS2 KRAS IL6 HRAS
26 12.22 TP53 MYC CTNNB1 APC
27 12.17 TP53 MYC KRAS IL6 HRAS
28
Show member pathways
12.16 TP53 MYC KRAS HRAS
29
Show member pathways
12.15 TP53 KRAS INS HRAS
30 12.12 MYC KRAS HRAS CTNNB1 APC
31
Show member pathways
12.1 TP53 KRAS INS HRAS
32
Show member pathways
12.1 KRAS INS IL6 HRAS
33 12.1 TP53 ODC1 MYC MSH2 KRAS CTNNB1
34 12.1 TP53 PTGS2 MYC MIR21 MIR17 MIR15A
35 12.08 TP53 MSH2 MLH1 APC
36 12.04 KRAS HRAS CTNNB1 APC
37 12.02 TP53 PTGS2 MYC IL6
38 12 TP53 MYC KRAS HRAS CTNNB1
39 11.99 TP53 PTGS2 MYC IL6
40 11.95 TP53 INS IL6 HRAS
41 11.91 TP53 MYC KRAS HRAS CTNNB1 APC
42 11.84 TP53 MYC KRAS HRAS CTNNB1 APC
43 11.82 TP53 ODC1 MYC
44 11.8 MYC CTNNB1 APC
45 11.76 TP53 MSH2 MLH1
46 11.76 TP53 MYC KRAS HRAS
47 11.73 TP53 KRAS HRAS
48 11.73 TP53 MYC KRAS HRAS
49 11.72 MYC CTNNB1 APC
50 11.71 TP53 MYC HRAS

GO Terms for Colorectal Adenoma

Biological processes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10 TP53 PTGS2 MYC MIR21 IL6 CTNNB1
2 negative regulation of gene expression GO:0010629 9.97 TP53 MIR21 MIR17 HRAS CTNNB1
3 response to drug GO:0042493 9.95 TP53 PTGS2 MYC MTHFR CTNNB1
4 cytokine-mediated signaling pathway GO:0019221 9.93 TP53 PTGS2 MYC KRAS IL6
5 cellular response to DNA damage stimulus GO:0006974 9.91 TP53 MYC MUTYH MSH2 MLH1 ERCC6
6 cellular response to hypoxia GO:0071456 9.86 TP53 PTGS2 MYC MIR17
7 positive regulation of cell proliferation GO:0008284 9.86 PTGS2 MYC MIR21 KRAS INS IL6
8 Ras protein signal transduction GO:0007265 9.85 TP53 KRAS HRAS
9 positive regulation of osteoblast differentiation GO:0045669 9.82 MIR21 IL6 CTNNB1
10 response to glucocorticoid GO:0051384 9.82 PTGS2 KRAS IL6
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.81 MIR21 MIR15A APC
12 positive regulation of MAPK cascade GO:0043410 9.8 INS IL6 HRAS CTNNB1
13 cellular response to UV GO:0034644 9.79 TP53 PTGS2 MYC
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR21 MIR17 HPGD
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.76 MIR21 IL6 CTNNB1
16 negative regulation of cell proliferation GO:0008285 9.76 TP53 PTGS2 MIR21 MIR15A IL6 HRAS
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.75 MSH2 MLH1 ERCC6
18 cell cycle arrest GO:0007050 9.72 TP53 MYC MSH2 HRAS APC
19 mismatch repair GO:0006298 9.69 MUTYH MSH2 MLH1
20 regulation of neuroinflammatory response GO:0150077 9.68 PTGS2 IL6
21 methionine biosynthetic process GO:0009086 9.67 MTR MTHFR
22 positive regulation of metalloendopeptidase activity GO:1904685 9.67 MIR21 MIR17
23 endothelial tube morphogenesis GO:0061154 9.66 MIR21 CTNNB1
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.66 MSH2 MLH1
25 ovulation GO:0030728 9.65 PTGS2 HPGD
26 response to UV-B GO:0010224 9.65 MSH2 ERCC6
27 response to gamma radiation GO:0010332 9.65 TP53 MYC ERCC6
28 response to isolation stress GO:0035900 9.64 KRAS HRAS
29 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.63 MIR21 IL6
30 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.62 MIR21 MIR17
31 negative regulation of blood vessel diameter GO:0097756 9.62 PTGS2 INS
32 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.61 MIR21 MIR17 IL6
33 positive regulation of isotype switching to IgA isotypes GO:0048298 9.6 MSH2 MLH1
34 somatic recombination of immunoglobulin gene segments GO:0016447 9.59 MSH2 MLH1
35 response to X-ray GO:0010165 9.58 TP53 MSH2 ERCC6
36 positive regulation of apoptotic process GO:0043065 9.56 TP53 PTGS2 MIR21 MIR15A IL6 HPGD
37 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.46 MSH2 MLH1
38 positive regulation of gene expression GO:0010628 9.28 TP53 MYC MIR21 KRAS INS IL6

Molecular functions related to Colorectal Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.85 TP53 MSH2 MLH1 ERCC6 CTNNB1
2 protein C-terminus binding GO:0008022 9.73 MSH2 HRAS ERCC6 CTNNB1
3 protein-containing complex binding GO:0044877 9.65 MYC MTHFR KRAS HRAS ERCC6
4 enzyme binding GO:0019899 9.55 TP53 PTGS2 MSH2 MLH1 CTNNB1
5 MutSalpha complex binding GO:0032407 9.4 MUTYH MLH1
6 MutLalpha complex binding GO:0032405 9.37 MUTYH MSH2
7 oxidized purine DNA binding GO:0032357 9.32 MUTYH MSH2
8 mRNA 3'-UTR binding GO:0003730 9.26 TP53 MIR21 MIR17 MIR15A
9 guanine/thymine mispair binding GO:0032137 8.62 MSH2 MLH1

Sources for Colorectal Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....